



## **Technical Report No. 69**

# **Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations**



## **PDA Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations Technical Report Team**

---

### **Authors and Contributors**

---

**Vince Anicetti**, Coherus Biosciences (Team Co-leader)

**Marc Mittelman**, Ph.D., Exponent (Team Co-leader)

**Catherine Adley**, Ph.D., University of Limerick

**Peter Amin**, Ph.D., U.S. FDA

**John Arigo**, Ph.D., U.S. FDA

**Hal Baseman**, Valsource, LLC

**John Paul Bevel**, Teva Pharmaceutical

**Lucia Clontz**, Ph.D., Xellia Pharmaceuticals

**Sven Deutschmann**, Ph.D., Roche Diagnostics GmbH

**Rebecca A. Devine**, Ph.D., Consultant to the Biopharmaceutical Industry

**Mark Fornalik**, Industrial Biofouling

**Patricia Hughes**, Ph.D., U.S. FDA

**Anastasia Lolas**, Visionary Pharma Consulting LLC

**Randa Melhem**, Ph.D., U.S. FDA

**Peter Noverini**, Azbil North America — BioVigilant Division

**Mark Pasmore**, Ph.D., Baxter

**T.C. Soli**, Ph.D., Soli Pharma Solutions, Inc.

**Paul Sturman**, Ph.D., Center for Biofilm Engineering

**Kalavati Suvarna**, Ph.D., U.S. FDA

**Tyler Tsang**, Genentech

**George Verghese**, STERIS Corporation

**Carmen M. Wagner**, Ph.D., Strategic Compliance International, Inc.

**DISCLAIMER:** The content and views expressed in this technical report are the result of a consensus achieved by the authoring task force and are not necessarily views of the organizations they represent.

# **Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations**

**Technical Report No. 69**

ISBN: 978-0-93-945976-6

© 2015 Parenteral Drug Association, Inc.

All rights reserved.



# Table of Contents

<b>1.0 INTRODUCTION</b> .....	<b>1</b>	4.2.6 Materials.....	22
1.1 Scope and Purpose .....	1	4.2.6.1 Raw Material Sources .....	23
<b>2.0 GLOSSARY OF TERMS</b> .....	<b>3</b>	4.2.6.2 Raw Material Handling .....	23
<b>3.0 OVERVIEW OF BIOBURDEN AND BIOFILMS</b> .....	<b>6</b>	4.2.6.3 Material Container Handling .....	23
3.1 Bioburden Generation .....	6	4.3 Cleaning and Sanitization Program.....	23
3.2 Chemistry of Biofilm Formation .....	7	4.3.1 Types of Residues .....	24
3.3 Growth and Survival .....	8	4.3.2 Cleaning Processes.....	24
3.4 Microbial By-Products .....	8	4.3.2.1 Water Flush or Rinse .....	24
3.4.1 Endotoxins and Other Cell-Wall Components.....	8	4.3.2.2 Sanitization .....	24
3.4.2 Exotoxins and Other By-Products .....	8	<b>5.0 BIOBURDEN AND BIOFILM DETECTION AND CHARACTERIZATION</b> .....	<b>26</b>
3.5 Impact of Fluid Flow on Biofilms.....	9	5.1 Sampling Points and Frequency.....	26
3.6 Biofilm-Remediation Considerations .....	11	5.1.1 Upstream Production.....	26
<b>4.0 DESIGN, CONTROL, AND PREVENTION CONSIDERATIONS</b> .....	<b>13</b>	5.1.2 Downstream Processing.....	27
4.1 Overview of Microbial-Control Strategy.....	13	5.1.3 Monitoring Strategy.....	27
4.1.1 Quality System.....	14	5.1.4 Process Sampling .....	27
4.1.2 Risk Assessment .....	14	5.1.5 Equipment Sampling .....	28
4.1.2.1 Ingress of Microorganisms.....	14	5.2 Sampling Strategy .....	28
4.1.2.2 Proliferation of Microorganisms.....	14	5.3 Microbial Levels and Limits .....	28
4.1.2.3 Persistence of Microorganisms .....	15	5.3.1 Environmental Contamination Recovery Rates.....	29
4.2 Design Considerations .....	15	5.4 Recovery and Analysis of Biofilms.....	30
4.2.1 Facility Design.....	15	5.4.1 Biofilm Sampling.....	30
4.2.1.1 Construction Materials .....	15	5.4.2 Biofilm Analyses .....	31
4.2.1.2 Cleaning Program .....	15	5.5 Microbial By-Product Detection .....	33
4.2.1.3 Environmental Controls.....	16	5.5.1 Endotoxins .....	33
4.2.1.4 Workflow .....	16	5.5.2 Other Microbial By-Products.....	34
4.2.1.5 Waste .....	17	5.6 Alternative Microbial-Detection Methods .....	34
4.2.2 Equipment Design.....	17	5.6.1 Rapid Microbial Methods (RMMs).....	34
4.2.2.1 Soft Part Management.....	17	5.7 Microbial Test Method Validation.....	36
4.2.2.2 Leak Control.....	18	5.7.1 Method Suitability .....	36
4.2.2.3 Automation.....	18	5.7.2 Alternative Method Validation.....	37
4.2.2.4 Cleaning.....	18	5.7.2.1 Microscopy.....	37
4.2.2.5 Equipment Hold Time and Storage .....	18	5.7.2.2 Spectroscopy.....	37
4.2.3 Water Systems and Gas Utilities Designs .....	19	5.7.2.3 Chromatography .....	37
4.2.3.1 Water Quality.....	19	5.8 Approaches to Laboratory Investigations .....	37
4.2.3.2 Water System Sanitization .....	19	5.8.1 Launching Investigations .....	37
4.2.3.3 Hose and Valve Maintenance .....	20	5.8.2 Investigation Outcomes .....	38
4.2.3.4 Process Gases .....	20	<b>6.0 INVESTIGATION AND REMEDIATION</b> .....	<b>39</b>
4.2.4 Manufacturing-Process Design.....	20	6.1 Organizing the Investigation Effort .....	39
4.2.4.1 Single-Use Technology .....	21	6.1.1 Formation of Investigation and Remediation Teams.....	39
4.2.4.2 In-Process Limits .....	21	6.2 Investigation .....	40
4.2.4.3 In-Process Hold Times.....	21	6.2.1 Verification of Initial Deviation Results .....	40
4.2.5 Personnel .....	22	6.2.1.1 Retesting, Resampling, and Collection of Additional Samples.....	40
		6.2.1.2 Review of the Sampling Procedure.....	40

6.2.1.3 Review of Laboratory Environmental and Test Controls .....	41	7.1.3 The Investigation .....	48
6.2.1.4 Microbial identification .....	41	7.1.4 Root and Probable Causes .....	49
6.2.2 Root Cause Determination of Contamination.....	41	7.1.5 CAPAs.....	49
6.2.2.1 Risk Assessment.....	41	7.1.6 Verification of Effectiveness.....	49
6.2.2.2 Investigation of the Contamination Source .....	42	7.1.7 Lessons Learned .....	49
6.2.2.3 Investigation Considerations.....	43	7.2 Scenario 2: Biofilm in WFI System .....	49
6.2.2.3.1 Species of Contaminant(s).....	43	7.2.1 System and Process Description .....	49
6.2.2.3.2 Association with Recent Changes to the System or Past Problems .....	43	7.2.2 The Event.....	50
6.2.2.3.3 Supplemental Nonroutine Sampling .....	43	7.2.3 The Investigation .....	50
6.3 Remediation.....	43	7.2.4 Root and Probable Causes .....	50
6.3.1 Issues to Consider in Biofilm Removal .....	43	7.2.5 CAPAs.....	50
6.3.2 Cleaning and Sanitization Methods and Parameters.....	44	7.2.6 Verification of Effectiveness.....	50
6.3.2.1 Cleaning Step(s) for Biofilm Removal ..	44	7.2.7 Lessons Learned .....	50
6.3.2.2 Achieving Microbial Kill after Cleaning	44	7.3 Scenario 3: Insufficient Hot Water Sanitization of a Cold WFI Loop .....	50
6.3.2.3 Rinsing of Cleaning Agents and Disinfectants.....	45	7.3.1 System and Process Description .....	50
6.3.3 Equipment Replacement or Design Improvement.....	45	7.3.2 The Event.....	51
6.3.4 Preventive Actions.....	45	7.3.3 The Investigation .....	51
6.3.4.1 Ineffective Routine Sanitization Parameters .....	45	7.3.4 CAPAs.....	52
6.3.4.2 Untreated Surfaces.....	45	7.3.5 Verification of Effectiveness.....	52
6.3.4.3 Revision of Cleaning and Sanitization Indicators or Frequency .....	46	7.3.6 Lessons Learned .....	52
6.3.4.4 Correction of Poor Equipment or Process Design.....	46	7.4 Scenario 4: Contaminated Purified-Water Loop Due to Open Point-of-Use Dead Leg .....	52
6.4 Monitoring CAPA Effectiveness .....	46	7.4.1 System and Process Description .....	52
6.5 Communication of Investigation Results and Actions.....	46	7.4.2 The Event.....	52
6.5.1 Reviews of Risk-Assessment Reports .....	46	7.4.3 The Investigation .....	53
6.5.2 Regulatory Submission Notification or Modifications.....	46	7.4.4 CAPAs.....	53
6.5.3 Notification of Customers and Suppliers about Changes.....	46	7.4.5 Verification of Effectiveness.....	53
		7.4.6 Lessons Learned .....	53

**7.0 CONTAMINATION SCENARIOS .....48**

7.1 Scenario 1: Biofilm in Biologics Purification Equipment.....	48
7.1.1 System and Process Description .....	48
7.1.2 The Event.....	48

**8.0 APPENDIX I: BIOPROCESS UNIT OPERATIONS AND TYPICAL PROCESS CONTROLS AND DETECTION .....56**

**9.0 APPENDIX II: TYPICAL BACTERIAL RESPONSE LIMITS FOR BIOPROCESSING .....58**

**10.0 REFERENCES .....59**

## FIGURES AND TABLES INDEX

<b>Figure 3.1-1</b>	Bacterial biofilm on 316 stainless steel.. 6	<b>Table 5.4.2-1</b>	Biofilm Analysis Methods ..... 32
<b>Figure 3.1-2</b>	Biofilm Formation and Generation..... 7	<b>Table 5.4.2-2</b>	Biofilm Analysis Techniques Using Removable Coupons ..... 32
<b>Figure 3.5-1</b>	Fluid-Flow Velocity Profiles for Laminar (a) and Turbulent (b) Flow Conditions within a Pipe ..... 10	<b>Table 5.5-1</b>	Possible Effects of Biofilm on Product..... 33
<b>Figure 3.5-2</b>	Laminar Boundary Sublayer Thickness in a Two-Inch Pipe..... 10	<b>Table 5.5-2</b>	Possible Effects of Biofilm on Process Performance ..... 33
<b>Fig 4.0-1</b>	Effective (Risk-Based, Science-Based, and Proactive) Microbial-Control Program ..... 13	<b>Table 5.6.1-1</b>	Current RMM Technologies ..... 35
<b>Figure 5.1-1</b>	Microbial Contamination Control in Bioprocessing ..... 26	<b>Figure 6.0-1</b>	Flow Diagram of Investigation and CAPA Steps for Effective Remediation ..... 39
<b>Table 5.4.1-1</b>	Biofilm Recovery/Analysis Methods .. 31	<b>Figure 6.2.2.1-1</b>	Fault-Tree Analysis to Determine the Root Cause of a Contamination..... 42

# 1.0 Introduction

In the pharmaceutical industry, microbial-control issues are frequently cited in U.S. FDA inspectional observations and have resulted in recalls and/or medical shortages (1). In a review of more than 600 microbiology-related U.S. recalls of sterile and nonsterile products from 2004 to 2011, the majority resulted from a “lack of sterility assurance,” indicating a potential problem with the product or packaging or that the manufacturer was unable to document that the product was manufactured in a state of control (2). Within the manufacturing environment, poor procedures, practices, and controls during the manufacture of sterile drug products and poorly designed environmental monitoring programs are frequent inspectional observations. Persistent bioburden and biofilm contamination have been implicated in at least one major recall that resulted in a medical shortage of parenteral products (1).

Management of bioburden, primarily biofilms, in pharmaceutical production processes is a major focus of quality programs. Yet, despite the significant resources used in bioburden contamination control efforts, bioburden contamination of manufacturing processes can be a significant cause of compromised product quality and adverse regulatory findings. Reasons for the persistent challenge of bioburden control include production processes that support microbial growth, use of nonsterile source materials, and human interfaces. This challenge is further complicated by the ability of microorganisms to survive and often flourish even in harsh environments (e.g., exposure to chemical sanitizers and disinfectants, high shear, and pressure). The formation of complex, adherent bacterial colonies (“biofilms”) in fluid handling systems is a common adaptive strategy for many microorganisms and presents a significant challenge for their detection and control. Microorganisms growing within biofilms, along with planktonic cells that are present in a bulk phase environment, comprise bioburden in fluid handling systems.

In the latter part of the 20<sup>th</sup> century, there was a fundamental shift in the understanding of microbial growth in various environments. The commonly held historical perception of bioburden was that it consisted of individual planktonic (free-floating) organisms. The planktonic model has been the basis for most current bioburden management strategies; nearly all of the commercially available bioburden detection systems are based on planktonic cell detection. However, evidence accumulated over the past three decades suggests that biofilms are actually the preferred mode of microbial growth (3-5), with sessile cells sometimes outnumbering planktonic organisms by several orders of magnitude in a given environment. Since the planktonic model does not provide for adequate detection and control of biofilms, there is a need for an increased focus on the development of effective strategies and techniques for the detection and control of biofilms in overall bioburden prevention and control activities.

Microbial and, in particular, biofilm control remains a major challenge for the medical device and pharmaceutical industries. Similarly, in hospitals and other healthcare institutions, a knowledge gap exists in the detection and control of biofilm-related infections (6).

## 1.1 Scope and Purpose

A comprehensive program of bioburden management includes strategies for preventing and controlling biofilms and is based on current scientific knowledge of microbial growth and adaptation. This technical report presents the current scientific understanding of the causes of, and control strategies for, bioburden in pharmaceutical production systems, with a special emphasis on biofilms in fluid-handling systems. The scope of the report encompasses pharmaceutical and biopharmaceutical manufacturing processes but does not include final aseptic and terminal sterilization fill-finish operations. It is important to educate engineers, scientists and managers about the science of bioburden and biofilms because of the broad and complex challenge of bioburden management.